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Abstract
Background: The purpose of this study was to explore molecular epidemiology of HCV genotype 3a in Peshawar
based on sequencing and phylogenetic analysis of Core region of HCV genome.
Methods: Chronically infected Hepatitis C virus infected patients enrolled under the Prime Minister Hepatitis C control
program at three Tertiary care units of Peshawar [Khyber Teaching Hospital Peshawar, Lady Reading Hospital Peshawar,
Hayat Abad Medical Complex Peshawar] were included in this cross sectional observational study. Qualitative detection
of HCV and HCV genotyping was carried out by a modified reverse transcription-polymerase chain reaction (RT-PCR)
and type specific genotyping assay. The Core gene of HCV genotype 3a was amplified, cloned and sequenced. The
sequences obtained were used for phylogenetic analysis using MEGA 6 software.
Results: Among the 422 (82.75 %) PCR positive samples, 192 (45.5 %) were identified as having HCV genotype 3a
infection. HCV Core gene sequencing was carried out randomly for the characterization of HCV 3a. Nucleotide
sequence analysis of the obtained viral genomic sequences based on partial HCV 3a Core gene sequences with
reference sequences from different countries showed that our sequences clustered with some local and regional
sequences with high bootstrap values.
Conclusion: HCV 3a is highly prevalent in Peshawar, Pakistan and its phylogenetics based on Core gene sequences
indicate the prevalence of different lineages of HCV 3a in Peshawar which may have consequences for disease
management strategies causing more economic pressure on the impoverished population due to possible antiviral
resistance.
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Background
Hepatitis C virus (HCV), first identified in 1989 is the pri-
mary cause of chronic liver diseases including cirrhosis
(60–85 %) and hepatocellular carcinoma [1], with an an-
nual mortality rate of 3.5-5.5 million due to complications
of end stage liver diseases [2]. An estimated 185 million
people (3 % of the world’s population) are infected world-
wide with relatively high prevalence rates in developing
countries [3, 4]. In Pakistan, approximately 10–17 million
people are chronically infected with HCV [5, 6] with an
overall prevalence rate of 5 % [7]. Frequency of HCV in-
fection differs among the four provinces with an estimated
1.1 million people infected in KPK [8, 9].
HCV is an enveloped, positive sense ssRNA genome
[10] in the family Flaviviridae consisting of an oral
reading frame (ORF) approximately of 9.6 kb in length
[11]. HCV genome shows substantial nucleotide se-
quence variability in both the structural and nonstruc-
tural coding regions, with different isolates of HCV
showing as much as 30 % nucleotide sequence diver-
gence over the entire genome which is sufficient to
alter the antigenic and biological characteristics of
seven major genotypes of HCV [12]. These genotypes
have distinct geographical distributions. Although HCV
genotypes 1, 2 and 3 appear to have a worldwide
distribution, their relative prevalence varies from one geo-
graphic area to another [13]. Identification of HCV geno-
type is extremely important as different genotypes are
relevant to the epidemiology and clinical management of* Correspondence: ijaz.ali@fulbrightmail.org2Department of Biosciences, COMSATS Institute of Information Technology
Islamabad, Islamabad, Pakistan
Full list of author information is available at the end of the article
© 2016 Gul et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gul et al. BMC Infectious Diseases  (2016) 16:163 
DOI 10.1186/s12879-016-1488-0
chronic HCV infection and is the strongest predictive par-
ameter for sustained virological response [14].
The primary means to identify and classify new geno-
types is either by phylogenetic analysis of sequences or
by measures of pairwise sequence similarity [15]. Al-
though it is generally true that longer sequences are
more informative for classification, it is usually possible
to identify genotypes by sequence comparison of rela-
tively short sub genomic regions of HCV [16]. While
region encoding the 5′ non-coding region (5′ NCR) is
too conserved for HCV subtypes identification, sequen-
cing and phylogenetic analysis of nucleotide sequences
amplified in the region of the genome encoding the
Core protein is frequently used for classification of
HCV into genotypes and subtypes [17–19]. HCV Core
gene has sufficient genetic diversity and can produce
topologically identical trees to those obtained upon
analysis of complete genome sequences [20].
Molecular epidemiological studies previously conducted
in Peshawar, Pakistan have indicated that the most preva-
lent HCV subtype is 3a accounting for 70–90 % of HCV
infections based solely on type specific PCR based geno-
typing methods developed 15 to 20 years ago [21, 22]. At
present, there is little information about the genetic his-
tory and evolution of HCV genotype 3a in Peshawar
which needs to be investigated for several reasons includ-
ing increasing antiviral resistance in the case of HCV 3a
in Peshawar, KP province and its evolutionary relationship
with other regional or global isolates. As the prevalence of
HCV 3a has been reported to be very high among the
general population of Peshawar, therefore, we embarked
on the current study to investigate it at molecular level by
Type-specific assay, sequencing of the Core gene and
phylogenetic analysis in order to have a clear epidemio-
logical picture of the prevalent HCV 3a isolates.
Methods
Sampling
Chronically infected Hepatitis C virus infected patients
enrolled under the Prime minister Hepatitis C control
program at three Tertiary care units [Khyber Teaching
Hospital Peshawar, Lady Reading Hospital Peshawar,
Hayat Abad Medical Complex Peshawar] willingly par-
ticipated in this observational study. A non-probability
convenient sampling technique was used to collect
data. Written consent was obtained from all the eli-
gible study participants for participation and publica-
tion of the data and the Institutional Ethics Committee
(Khyber Medical University Ethics Board) approved
the study. Blood samples were collected from the pa-
tients in sterile vacutainers and sera extraction was
carried out at the Institute of Biotechnology and Gen-
etic Engineering Peshawar.
RNA Extraction
Total RNA was extracted from each sample using Favor-
Gen RNA isolation Kit (Favorgen Biotech corp, Taiwan,
CAT No FAVNK 001) according to the manufacturer’s
instructions. The isolated RNA was stored either stored
at-80C or immediately used for RT PCR.
HCV Genotyping
Reverse Transcription PCR followed by Type-specific
PCR for identification of HCV subtypes was carried out
essentially according to [23] with modifications in the
Universal and Type-specific primers according to the
latest HCV sequencing data (Table 1).
Amplification of HCV 3a Core gene
A representative number of samples (58/192), which
turned out positive for HCV 3a by the Type-specific
assay described earlier, were used for a second round of
RNA extraction, RT PCR and subsequent regular nested
PCR for the amplification of Core gene using gene-
specific primer [24].
Cloning and sequencing of the Core gene
The Core gene products were eluted from agarose gel
using Pure Link™ Quick Gel Extraction Kit (https://
www.thermofisher.com/pk/en/home.html). The eluted
products were cloned in pGEMT-Easy vector and
transformed in DH5-alfa strain of E.coli (Promega). Se-
quencing PCR of the Core gene was carried out using
vector-specific sense and antisense primers in a sequencing
PCR (Big Dye Deoxy Terminator method). Bidirectional
sequencing run was performed using ABI PRISM 310
DNA sequencer [Applied Biosystems].
Blast analysis
In case of each isolate, three independent clones were
sequenced. The respective sequences were aligned and
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consensus sequences were derived. The sequences were
blasted using NCBI Blast tool and genotype authentication
was further validated with the help of an online software
HCV Genotyper (http://www.bioafrica.net/rega-genotype/
html/subtypinghcv.html). The confirmed and curetted
sequences representing the diversity of 58 sequenced
isolates were submitted to GenBank
Phylogenetic analysis
HCV Core gene sequences from various geographical
regions of the world were retrieved from the online
sequence repositories and Phylogenetic tree was con-
structed by using Mega6 [25].
Statistical analysis
SPSS version 20 was used for data analysis. The qualita-
tive variables were described using percentage and the
quantitative variables were described using the mean,
median and standard deviation.
Results
For identification of HCV genotype 3a infection among
the actively infected HCV samples, RT PCR followed by
Type specific nested PCR based genotyping assay was
carried out. Genotyping analysis revealed that out of the
422 (82.75 %) samples processed. Out of 422 actively in-
fected patients, 257 (61 %) were females and 165 (39 %)
were male) HCV genotype 3a was identified as the most
abundant HCV subtype 192 (45.50 %). Mean age of pa-
tients included in the study was 38 ± 11.8 (Mean ± SD.
For authentication of HCV genotype 3a, Core gene amp-
lification and sequencing was carried out by randomly
selecting a representative number (58/192) of samples
and it was established that the patients had HCV 3a in-
fection. These results were also validated by an online
sub-typing tool (http://www.bioafrica.net/rega-genotype/
html/subtypinghcv.html). Detailed sequence and phylo-
genetic analysis of the obtained viral genomic sequences
was carried out. Phylogenetic tree was developed with
Maximum Likelihood algorithm (1000 bootstrap repli-
cates). To analyze HCV genotype 3a of Peshawar origin,
the available subtype 3a sequences of the Core gene were
retrieved from NCBI and aligned with the respective
subtype identified in this study. Pair wise nucleotide and
deduced amino acid sequence comparison of our se-
quences with 36 reported sequences from different
countries was performed which indicated that some of
the HCV 3a isolates of Peshawar clustered together with
each other and with isolates from Pakistan (KP869047,
KP869048, KP869049, KP869055, KP869056, KP869057,
KP869058), while others clustered closer to European,
Indian, Iranian or Chinese HCV sequences with high
bootstrap support (Fig. 1). Two of the representative iso-
lates (KP869053 and KP869054) were clustered with the
European isolates. Isolate KP869050 and KP869051 shared
homology with both the Indian, Iranian and Chinese iso-
lates. Moreover isolate KP869052 was found closely re-
lated to those from Iran and Pakistan.
Discussion
Accumulation of nucleotide substitutions in the HCV
genome results in diversification and evolution into
seven major genotypes and a series of subtypes [26]. The
classification of HCV by viral genotype is not only im-
portant for appropriate treatment regimen and assess-
ment of global viral evolution but their epidemiological
data can reveal transmission activity and migration
movement of infected individuals from the endemic area
[27–29]. These viral types and subtypes show differing
distribution in different geographic regions which have
provided investigators with an epidemiologic marker
that can be used to trace the source of HCV infection in
a given population [30]. Sequencing and phylogenetic
analysis of HCV Core gene nucleotide sequences has
earlier been used for identification and classification of
HCV isolates into genotypes and subtypes [19]. HCV
genotype 3a is the most abundant in Pakistan and it has
earlier been documented that HCV genotype 3a is rela-
tively more responsive to therapy as compared to geno-
type 1 or 4 [28, 29, 31]. However, in Pakistan resistance
is being observed in case of relatively responsive and
easy to treat HCV genotype 3a [32].
The present study is the first report describing the
genotypic and evolutionary analysis of HCV 3a isolated
from chronic HCV infected patients of Peshawar, based
on a modified genotyping assay and subsequent sequen-
cing and phylogenetic analysis. Investigation of the dif-
ferent circulating genotypes and their evolution is not
only crucial for epidemiological and clinical analysis but
might be helpful for the improvement of diagnostic tests
and treatment regimens [33]. HCV infection is highly
prevalent in Pakistan with an overall prevalence rate of
5 % [34]. The estimated HCV prevalence in KP province
is 1.1 % [8]. In this study, out of total 510 seroactive pa-
tients investigated, 82.75 % were actively infected with
HCV having high proportion of HCV genotype 3a
(45.50 %) which is in agreement with most recent stud-
ies in Peshawar and Pakistan reporting HCV 3a to be
the most prevalent genotype [35, 36], however the per-
centage prevalence is lower than the previous reports
claiming much higher prevalence of HCV genotype 3a
(60–74 %) [22, 37]. One possible explanation for this
changing HCV genotype 3a landscape could be the
change in epidemiological pattern over times as a result
of people migration [38] or the inadequate sensitivity of
old genotyping assays to correctly type the circulating
viral strains due to substantial genetic heterogeneity
inherent to RNA viruses [26]. Moreover the emerging























































Fig. 1 Phylogenetic tree of HCV 3a Core gene sequences constructed by Maximum Likelihood algorithm (MEGA 6 Software) with Bootstrap values
shown on the branches. Tree shows the phylogenetic relationship of twelve newly reported sequences, marked in red with 36 Core gene sequences
from different geographical regions. The isolate/country/Accession no of the sequences are shown in figure
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resistance to interferon therapy experienced in case of
HCV genotype 3a [32] might possibly be due to the less
prevalent genotypes other than HCV 3a or variants of
HCV 3a evolved overtimes which can cause substantial
economic and health burden over the infected popula-
tion. Internationally accepted guidelines for the treat-
ment of hepatitis C are rarely followed in KPK and
people undergo successive therapies once the initial re-
sponse of antiviral drugs is negative [32]. Due to lack of
awareness, the practice mentioned above is not only
causing economic and health related losses but is also
contributing towards the evolution of more resistant
HCV 3a types.
Molecular evolutionary analysis of the obtained viral
genome sequences revealed that some HCV 3a isolates
of Peshawar clustered closer to local isolates (Fig. 1)
indicating the previous existence of similar types in
other parts of Pakistan, which may have spread to Pe-
shawar, KPK province via various transmission routes.
Some of the HCV 3a isolates grouped with European,
south Asian, Iranian and Chinese HCV 3a isolates
(Fig. 1). Peshawar city is located in the northwestern
region of Pakistan. It shares international border with
the Afghanistan which has been home to conflicts for
the past 40 years resulting in migration of various eth-
nic groups into and out of Afghanistan. These migra-
tions have changed epidemiological patterns of various
pathogens overtimes including HCV. Phylogenetic
analysis indicate that foreign presence in Afghanistan
and migration of Afghanis to Peshawar might have
contributed towards the spread of isolates which are
genetically closer to European, Indian, Chinese and
Iranian isolates as HCV genotype 3a is also highly
prevalent in neighboring countries including China
[38], India [39] and Iran [40].
This study has some limitations. Due to convenient
sampling, selection bias might have occurred. Moreover
we have characterized HCV 3a entirely on the bases of
partial core gene sequences. To elucidate the epidemi-
ology of emerging HCV 3a in Peshawar and to further
improve the accuracy of diagnostic assays and treatment
regimens, there is a need to analyze complete coding se-
quences of more diverse regions of HCV genome on a
comparatively large scale.
Conclusion
This study concludes that HCV 3a is highly prevalent in
Peshawar, Pakistan and its phylogenetics based on Core
gene sequences indicate the prevalence of different line-
ages of HCV 3a in Peshawar which may have conse-
quences for disease management strategies causing more
economic pressure on the impoverished population due
to possible antiviral resistance.
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